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Abstract
Stenotrophomonas maltophilia is a nosocomial pathogen associated with high morbidity and mortality, particularly in
immunocompromised or critically ill patients. In this study, we investigated the risk factors for mortality in patients with S. maltophilia
bacteremia.
Retrospectively, medical records from all patients with S. maltophilia bacteremia between December 2005 and 2014 at Severance
Hospital, a 2000-bed tertiary care hospital in Seoul, Korea, were reviewed. Analysis was performed to identify factors associated with
28-day mortality.
In total, 142 bacteremia patients were enrolled in this study. The overall 28-day mortality rate was 36.6%. Based on the univariate
analysis, hematologic malignancy (P=0.015), Sepsis-related Organ Failure Assessment (SOFA) score (P<0.001) and the removal of
a central venous catheter (CVC) (P=0.040) were signiﬁcantly related to mortality. In the intensive care unit patients, the Acute
Physiology and Chronic Health Evaluation II score (P=0.001) also had signiﬁcance. Based on the multivariate analysis, the SOFA
score (odds ratio [OR]=1.323; 95% conﬁdence interval [CI]: 1.159, 1.509; P<0.001) and removal of the CVC (OR=0.330; 95% CI:
0.109, 0.996; P=0.049) were independent factors associated with mortality.
Our results suggest that removing a CVC may considerably reduce mortality in patients with S. maltophilia bacteremia.
Abbreviations: APACHE II score = Acute Physiology and Chronic Health Evaluation II score, CI = conﬁdence interval, CVC =
central venous catheter, ICU = intensive care unit, OR= odds ratio, PTBD = percutaneous transhepatic biliary drainage, SOFA score
= Sepsis-related Organ Failure Assessment score, TMP–SMX = trimethoprim–sulfamethoxazole.
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Stenotrophomonas maltophilia is a glucose non-fermentative,
Gram-negative bacillus that has the ability to colonize epithelial
cells of the respiratory tract and surfaces of medical devices.[1] It
has inherent resistance to several antibiotics such as carbapenem,
and the increasing use of antibiotics has allowed this bacterium to
become a predominant nosocomial pathogen.[2]
Predisposing factors of S. maltophilia infection are well known
and include CVCs, urinary catheters, mechanical ventilation,Editor: Susanna Esposito.
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1recent surgery, malignancies, admission to an intensive care unit
(ICU), immunosuppressive drugs, neutropenia, and prior
antibiotic use.[3,4] Pneumonia and bacteremia are the most
common clinical manifestations of S. maltophilia infection. Less
frequently, it can cause urinary tract infections, cholangitis,
peritonitis, wound infections, eye infections, arthritis, meningitis,
and endocarditis.[1]
S. maltophilia is associated with high morbidity and mortality,
ranging from 21 to 69%, and is particularly observed in
immunocompromised or critically ill patients.[5,6] Treatment of S.
maltophilia infection can be difﬁcult because of its inherent
resistance to a variety of antibiotics.[7,8] For S. maltophilia,
trimethoprim–sulfamethoxazole (TMP–SMX) is the drug of
choice, and ﬂuoroquinolone is the proposed alternative.
Several studies have reported the risk factors for mortality
associated with S. maltophilia infection.[2,4,9–18] However, these
studies have not shown consistent results, with some being
contradictory to others. Furthermore, it is difﬁcult to distinguish
betweenS.maltophilia colonization and infection,which canaffect
the results of studies focused on identifying the risk factors for
mortality.[3] Therefore, in our study, we utilized patients with S.
maltophilia bacteremia to investigate the risk factors formortality.2. Methods
2.1. Study population and design
A retrospective cohort study was conducted to evaluate the risk
factors for morality in S. maltophilia bacteremia at Severance
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were >18 years of age and tested positive for S. maltophilia in 1
or more blood cultures between December 2005 and 2014. For
patients that had more than 1 episode of S. maltophilia
bacteremia, only the ﬁrst episode was accepted. Clinical and
laboratory data were collected from electronic medical records,
including 28-day mortality. The Sepsis-related Organ Failure
Assessment (SOFA) score was calculated in all patients, and the
Acute Physiology and Chronic Health Evaluation (APACHE) II
score was calculated in ICU patients. This study was approved by
the Institutional Review Board and local Ethics Committee of
Severance hospital.2.2. Deﬁnitions
S. maltophilia bacteremia was deﬁned as a patient having 1 or
more positive blood culture, combined with clinical symptoms of
systemic inﬂammatory response syndromes.[11] Polymicrobial
bacteremia was deﬁned as 2 or more bacterial species identiﬁed in
multiple blood culture samples collected within 24 hours.[15]
Nosocomial bacteremia was deﬁned as occurring ≥48 hours after
admission. Healthcare-associated bacteremia was deﬁned as
bacteremia that occurs in a patient who has stayed in a nursing
home, has been admitted to a hospital within the previous month,
received hemodialysis, or has been treated as an outpatient with
intravenous antibiotics or chemotherapy within the previous 2
weeks. Community-acquired bacteremia was deﬁned as bacter-
emia that occurred within 48 hours of admission and in patients
who did not meet the criteria for healthcare-associated bacter-
emia.[10] The source of bacteremia was determined if there was an
active site of infection, and S. maltophiliawas identiﬁed from that
site immediately before—or the same day of—bacteremia
onset.[15] When blood cultures from the periphery and CVC
both tested positive for S. maltophilia in the absence of other
active sites of infection, we deﬁned this as a catheter-related
infection. Prior antibiotic use was deﬁned as any antibiotic
treatment for more than 24 hours within 1 month before the
episode of bacteremia.[19] Immunosuppressive therapy was
deﬁned as a daily dose of ≥10mg prednisolone-equivalent
steroid, monoclonal antibodies, antimetabolite drugs, or T-cell
inhibitors within 30 days before bacteremia onset.[20] Neutrope-
nia was deﬁned as an absolute neutrophil count of <500/mm3 at
the onset of bacteremia.[6] Empirical antibacterial therapy was
deﬁned as treatment that was initiated no later than 24 hours
after blood cultures were drawn. Deﬁnitive antibacterial therapy
was deﬁned as treatment that was continued or commenced after
blood culture results were reported and that was started no later
than 120 hours after blood cultures were drawn.[21] Antibacterial
therapy was regarded as appropriate if the targeted regimen
included at least 1 antibiotic agent to which S. maltophilia was
susceptible in vitro.[20] The removal of the CVC was deﬁned
when this was performed no later than 5 days after blood cultures
were drawn.2.3. Clinical techniques
Either conventional bacterial isolation techniques or the ATB 32
GN system (bioMérieux, Marcy l’Etoile, France) was used to
evaluate clinical isolates. Antimicrobial susceptibility tests were
performed using the disk-diffusion method or a VITEK-2 N131
card (bioMerieux, Hazelwood, MO). The results were inter-
preted on the basis of the Clinical and Laboratory Standards
Institute guidelines.22.4. Statistical analysis
Data were analyzed using SPSS for Windows (ver. 20.0, SPSS
Inc., Chicago, IL). Analysis was performed to assess the factors
associated with 28-day mortality. Student t test was used for
continuous variables and the Chi-square test or Fisher exact test
was used for categorical variables. A two-sided P value <0.05
was considered to be statistically signiﬁcant. Multiple logistic
regressions were performed to determine independent risk factors
for 28-day mortality, and the Kaplan–Meier method was utilized
for survival analysis.3. Results
3.1. Demographic characteristics
In total, 142 bacteremia patients were enrolled in this study.
Patient demographics are presented in Table 1. The median age
was 61 years, and 60 patients (42.3%) were >65 years. There
were 88 male (62.0%) and 54 female (38.0%) patients. The most
frequent underlying conditions were solid tumor (55.6%),
hematologic malignancy (23.2%), and diabetes mellitus
(16.2%). Polymicrobial bacteremia occurred in 38 patients
(26.8%). Common pathogens that were found concurrently with
S. maltophilia included enterococci in 12 patients, coagulase
negative staphylococci in 6 patients, Acinetobacter spp. in 6
patients, Serratia spp. in 4 patients, Candida spp. in 3 patients,
and Pseudomonas spp. in 3 patients. In 142 episodes of
bacteremia, 125 episodes (88.7%) were nosocomial, 14 (14%)
were healthcare-associated, and 2 (1.4%) were community-
acquired. Common sources of bacteremia included the respira-
tory tract in 48 patients (33.8%), CVC in 35 patients (24.6%),
and biliary tract in 32 patients (22.5%). Forty-four patients
(31.0%) were in the ICU when bacteremia occurred. There were
14 patients (9.9%) who received appropriate empirical antibac-
terial therapy and 55 (38.7%) that received appropriate deﬁnitive
antibacterial therapy. There were 21 patients (14.8%) treated
with TMP–SMX and 40 (28.2%) treated with levoﬂoxacin. A
CVCwas used in 95 patients (66.9%) and was removed from 27/
95 patients (28.4%). The mean time from drawing the blood
cultures to removal was 2.3±1.1 days. The 28-day mortality rate
was 36.6% (52/142).3.2. Antimicrobial susceptibilities
From the patients’ blood cultures, 16 isolated S. maltophilia
strains (11.3%) were resistant to TMP–SMX and 31 strains
(22.0%) were resistant to levoﬂoxacin.3.3. Risk factors for mortality in patients with S.
maltophilia bacteremia
A univariate analysis was performed to identify risk factors
associated with 28-day mortality (Table 1). Hematologic
malignancy (P=0.015), SOFA score (P<0.001), and removal
of the CVC (P=0.040) were signiﬁcantly related to mortality. In
the ICU patients, the APACHE II score (P=0.001) also had
signiﬁcance. Based on the multivariate analysis, the SOFA score
(odds ratio [OR]=1.323; 95% conﬁdence interval [CI]: 1.159,
1.509; P<0.001) and removal of the CVC (OR=0.330; 95%CI:
0.109, 0.996; P=0.049) were independent factors associated
with mortality (Table 2). Hematologic malignancy was not a
signiﬁcant independent factor when combined in the logistic
regression model. In addition, a Kaplan–Meier curve was drawn
Table 1
Overall characteristics and univariate analysis of 28-day mortality in patients with S. maltophilia bacteremia.
Characteristics Total n=142 (%) Survived n=90 (%) Death n=52 (%) P
Age, y; median, IQR 61.0 (49.5–70.0)
≥65 60 (42.3) 41 (45.6) 19 (36.5) 0.295
<65 82 (57.7) 49 (54.4) 33 (63.5)
Gender
Male 88 (62.0) 57 (63.3) 31 (59.6) 0.660
Female 54 (38.0) 33 (36.7) 21 (40.4)
BMI (kg/m2), mean±SD 22.4±3.8 22.3±3.7 22.5±4.0 0.685
Underlying disease
Solid tumor 79 (55.6) 51 (56.7) 28 (53.8) 0.744
Hematologic malignancy 33 (23.2) 15 (16.7) 18 (34.6) 0.015
Cardiovascular disease 11 (7.7) 8 (8.9) 3 (5.8) 0.746
Chronic lung disease 11 (7.7) 7 (7.8) 4 (7.7) >0.999
Chronic liver disease 18 (12.7) 11 (12.2) 7 (13.5) 0.831
Chronic kidney disease 8 (5.6) 7 (7.8) 1 (1.9) 0.258
Diabetes mellitus 23 (16.2) 17 (18.9) 6 (11.5) 0.252
Transplantation 14 (9.9) 10 (11.1) 4 (7.7) 0.510
Polymicrobial bacteremia 38 (26.8) 24 (26.7) 14 (26.9) 0.973
Acquisition of bacteremia
Nosocomial 126 (88.7) 79 (87.8) 47 (90.4) 0.636
Healthcare-associated 14 (9.9) 9 (10.0) 5 (9.6) 0.941
Community acquired 2 (1.4) 2 (2.2) 0 (0) 0.533
Source of bacteremia
CVC 35 (24.6) 19 (21.1) 16 (30.8) 0.198
Respiratory tract 48 (33.8) 26 (28.9) 22 (42.3) 0.103
Abdomen except biliary tract 6 (4.2) 5 (5.6) 1 (1.9) 0.415
Biliary tract 32 (22.5) 20 (22.2) 12 (23.1) 0.907
Urinary tract 2 (1.4) 1 (1.1) 1 (1.9) >0.999
Primary unknown 19 (13.4) 19 (21.1) 0 (0)
Bacterial resistance
TMP–SMX resistance 16 (11.3) 8 (8.9) 8 (15.4) 0.238
Levoﬂoxacin resistance 31 (22.0) 16 (18.0) 15 (28.8) 0.133
Predisposing conditions
Prior antibiotic use 137 (96.5) 85 (94.4) 52 (100) 0.158
Immunosuppressive therapy 20 (14.1) 11 (12.2) 9 (17.3) 0.401
Prior chemotherapy 33 (23.2) 21 (23.3) 12 (23.1) 0.972
Neutropenia 22 (15.5) 11 (12.2) 11 (21.2) 0.156
SOFA score, mean±SD 6.0±4.5 4.2±3.0 9.0±5.1 <0.001
ICU stay 44 (31.0) 25 (27.8) 19 (36.5) 0.277
APACHE II score, mean±SD† 14.1±6.6 11.3±4.6 17.8±7.0 0.001
Mechanical ventilation 34 (23.9) 19 (21.1) 15 (28.8) 0.298
Treatment
Appropriate empirical antibacterial therapy 14 (9.9) 8 (8.9) 6 (11.5) 0.610
Appropriate deﬁnitive antibacterial therapy 55 (38.7) 35 (38.9) 20 (38.5) 0.960
TMP–SMX 21 (14.8) 11 (12.2) 10 (19.2) 0.257
Levoﬂoxacin 40 (28.2) 27 (30.0) 13 (25.0) 0.523
CVC removal (n=95)‡ 27 (27/95, 28.4) 19 (19/51, 37.3) 8 (8/44, 18.2) 0.040
∗
APACHE II score= Acute Physiology and Chronic Health Evaluation II score, BMI= body mass index, ICU= intensive care unit, IQR= interquartile range, SOFA score= Sepsis-related Organ Failure Assessment
score, SD = standard deviation, TMP–SMX = trimethoprim–sulfamethoxazole, CVC = central venous catheter.
† APACHE II scores were calculated for the ICU patients.
‡ Total 95 patients had CVCs. Fifty-one patients were survived, and 44 patients were dead. The removal of CVC was performed in 19 of 51 survived patients and 8 of 44 dead patients.
Table 2
Multivariate analysis of factors associated with 28-day mortality in
patients with S. maltophilia bacteremia.
Factor OR (95% CI) P
Hematologic malignancy 2.149 (0.747, 6.178) 0.156
SOFA score 1.323 (1.159, 1.509) <0.001
CVC removal 0.330 (0.109, 0.996) 0.049
∗
CI = conﬁdence interval, CVC, central venous catheter, OR = odds ratio, SOFA score = Sepsis-
related Organ Failure Assessment score.
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3to estimate the impact of CVC removal on survival (Fig. 1).
Patients who had the CVC removed had signiﬁcantly higher
survival rates compared to those who did not have the catheter
removed (log-rank P=0.038).
4. Discussion
Our results show that S. maltophilia bacteremia patients with
high SOFA scores had higher rates of mortality, and that removal
of the CVC was a protective method to reduce mortality. Several
studies have focused on the risk factors for mortality of
Figure 1. Kaplan–Meier curve comparing survival between patients with and
without the removal of the central venous catheter.
∗
CVC = central venous
catheter.
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sizes.[5,6,10,11,13,15–17,19,20] In this study, we enrolled 142 patients;
to date, this is the largest study investigating risk factors for
mortality in patients with S. maltophilia bacteremia.
In our study, we identiﬁed SOFA score as an independent risk
factor associated with mortality, based on the results of our
multivariate analysis. Several studies have reported similar
results, as well as reporting that patient medical conditions were
more important factors associated with mortality than the
appropriateness of antibiotics.[10,13,22,23] In addition, our results
show that the appropriateness of antibiotics, as well as empirical
and deﬁnitive antibacterial therapy, was not associated with
mortality. However, other studies have reported that the
appropriate antibacterial therapy is signiﬁcantly associated with
lower mortality.[5,24,25] Further investigation to evaluate the
impact of appropriate antibacterial therapy should be performed.
We observed that the removal of the CVC was signiﬁcantly
associated with lower mortality, based on the results of our
multivariate analysis. Previous studies reported that many
patients with S. maltophilia bacteremia had CVCs because S.
maltophilia bacteremia occurs mainly in immunocompromised
or critically ill patients.[6,10] In addition, it is known that CVCs
may be a risk factor for S. maltophilia infections.[1] In our study,
95 patients (66.9%) had a CVC and 27/95 patients (28.4%) had
it removed. Some reports have suggested that the removal of the
CVC in patients with S. maltophilia bacteremia is beneﬁ-
cial.[15,19,24,26] More speciﬁcally, 3 studies have reported the
implications of removing the CVC in catheter-related infec-
tions.[15,19,26] However, our results suggest that removal was
related with lower mortality irrespective of the bacteremia
source in patients who had a CVC. Other studies have reported
similar results and suggested that this may imply colonization
rather than true source of bacteremia in cases in which S.
maltophilia was isolated from other sources like the respiratory
tract. These results suggest that in other cases, the CVC may be
the true source of infection.[24] Furthermore, we believe that the
CVCmay be an additional secondary source, although it was not
the primary source. Our study could strengthen the evidence
supporting the removal of the CVC to reduce mortality in all
bacteremia patients regardless of the presence of a catheter-
related infection.
In this study, common underlying conditions were solid tumor
(55.6%) and hematologic malignancy (23.2%). These results are4consistent with other studies, which indicate that these conditions
are associated with immunocompromised status after chemo-
therapy, use of medical devices, exposure to antibiotics, and long
hospital stays in cancer patients.[1] Based on the univariate
analysis, hematologic malignancy (P=0.015) was signiﬁcantly
related to mortality, but no signiﬁcance (P=0.156) was observed
in multivariate analysis. In 14 cases (9.9%), the patient was a
transplant recipient. As transplantation is increasing globally,
this couldmean an increase in patients prone to various infections
including S. maltophilia.[27]
Common sources of bacteremia were the respiratory tract
(33.8%), CVC (24.6%), and biliary tract (22.5%). The
respiratory tract and CVC s are well-known sources of S.
maltophilia infections.[1] The biliary tract was the source of
bacteremia in a large number of patients, and this may be due to
percutaneous transhepatic biliary drainage (PTBD) catheters. All
patients whose source of bacteremia was the biliary tract had
PTBD catheters, suggesting that this medical device may be a risk
factor for S. maltophilia infections.
Our study had several limitations. First, we included patients
from a single center, which may make it difﬁcult to apply our
results to other hospitals. Second, the design of our study was
retrospective. This type of study may have selection and
information biases. Third, the true source of bacteremia was
not easy to identify because it was not easy to distinguish between
colonization and infection when S. maltophilia was identiﬁed
from the sites other than blood. This would be related to the
possibility of identifying the incorrect source of infection. Lastly,
we used all-cause mortality as the primary end point, and this
indicates that the effect of underlying disease or other medical
condition was not excluded.
In conclusion, our results suggest that removal of the CVC
should be considered to reduce mortality in patients with S.
maltophilia bacteremia. In addition, we believe a well-designed
study to evaluate the impact of appropriate antibacterial therapy
is required.References
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